AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02082184 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Blood Glucose Monitoring
Description: Subjects will use an Abbott Blood Glucose Monitoring System (standard blood glucose meter) for 6 months to monitor their glucose levels. A 14-day masked wear of the Abbott Sensor Based Glucose Monitoring System is included for these subjects at the 6 month time point, to collect glycaemic variability data for comparison to the intervention group of the study.~All subjects will wear a masked Abbott Sensor Based Glucose Monitoring System, for 14 days prior to randomisation.
Study NCT03177252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: -2% lidocaine will be given
Study NCT03177252 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium chloride
Description: -Normal saline will be given
Study NCT03177252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: -0.5% bupivacaine will be given
Study NCT02187640 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-administered acupressure
Description: Self-administered acupressure: In order to ensure the compliance of treatment, they would apply this intervention according to the acupressure group protocol once per day in groups with one trained research nurse's instructions and supervision .
Study NCT02187640 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham control group
Description: Sham intervention: Patients received similar aupressure intervention on the non-acupoints.
Study NCT02832271 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SUNPHENON EGCg
Description: SUNPHENON EGCg Oral, 400mg, twice per day
Study NCT02832271 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT03279978 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Once per day (QD) on Days -1, 3, and 14. Dose groups BI 730357 200 mg fed and BI 730357 400 mg fed
Study NCT03228407 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic biopsies
Description: Additional biopsies will be obtained of the esophageal mucosa.These will be obtained with a standard biopsy forceps inserted through the channel in gastroscope.
Study NCT03228407 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Endoscopic biopsies
Description: Additional biopsies will be obtained of the esophageal mucosa.These will be obtained with a standard biopsy forceps inserted through the channel in gastroscope.
Study NCT03228407 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Mucosal impedance (MI)
Description: MI balloon measures epithelial impedance along a 10 cm length of esophagus. The gastroscope will be withdrawn and the MI balloon will be advanced into the esophagus through the mouth. The balloon will be inflated so that the sensors contact the esophageal mucosa. After MI measurements are obtained, the balloon will be deflated and withdrawn.
Study NCT03228407 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Mucosal impedance (MI)
Description: MI balloon measures epithelial impedance along a 10 cm length of esophagus. The gastroscope will be withdrawn and the MI balloon will be advanced into the esophagus through the mouth. The balloon will be inflated so that the sensors contact the esophageal mucosa. After MI measurements are obtained, the balloon will be deflated and withdrawn.
Study NCT00557102 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: cetuximab
Study NCT00557102 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: filgrastim
Study NCT00557102 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: fluorouracil
Study NCT00557102 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: irinotecan hydrochloride
Study NCT00840879 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meloxicam 15 mg Tablets
Description: 1 x 15 mg, single-dose fed
Study NCT00557102 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: leucovorin calcium
Study NCT03878459 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone 45 mg
Description: patients will be started on 15 mg and the dose escalated to the maximal tolerated dose
Study NCT03878459 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: PATIENTS WILL RECEIVE PLACEBO
Study NCT02505971 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nadolol
Description: Patients will be administered twice-daily doses of medication as follows: since Day 0- 0.5 mg/kg/day ; since Day 7-1.0 mg/kg/day and since Day 14- 1.5 mg/kg/day. In all subsequent visits the dosage will be adjusted based on the current weight rather than the baseline weight to maintain 1.5 mg/kg/day. Or the dose may be escalated (by 0.5 mg/kg/day at any following study visit) up to 3 mg/kg/day based on the clinical response to maintain the dose that led to at least 75% reduction in the hemangioma size until Week 24, when unblinding happen. At Week 24 paticipants can start weaning by 10% per week or continue with the last dose, depending on the investigator's decision.~S/he will be monitored until Week 52.
Study NCT00840879 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mobic® 15 mg Tablets
Description: 1 x 15 mg, single-dose fed
Study NCT06736626 — intervention group
Intervention type: DEVICE
Intervention: Percutaneous coronary intervention
Description: Percutaneous coronary intervention (PCI) is a catheter-based technique performed under fluoroscopic guidance to treat coronary artery disease and restore blood flow to the myocardium. During PCI, coronary vessel patency is generally achieved with drug-eluting stents (DES), which are metallic scaffolds coated with a polymer that carry and gradually release an antiproliferative drug. In the present study, all participants underwent PCI with implantation of DES, and received a subsequent course of dual antiplatelet therapy (DAPT), as clinically indicated.
Study NCT02505971 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propranolol
Description: Patients will be administered twice-daily doses of medication as follows: since Day 0- 0.5 mg/kg/day ; since Day 7-1.0 mg/kg/day and since Day 14- 1.5 mg/kg/day.~In all subsequent visits the dosage will be adjusted based on the current weight rather than the baseline weight to maintain 1.5 mg/kg/day. Or the dose may be increased by investigator, based on clinical response by 0.5 mg/kg/day at any study visit (up to 3 mg/kg/day divided twice a day) to maintain the dose that lead to at least 75% reduction in the hemangioma size until Week 24, when unblinding happen. At Week 24 paticipants can start weaning by 10% per week or continue with the last dose, depending on the investigator's decision.~S/he will be monitored until Week 52.
Study NCT02907944 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Implementation Facilitation
Description: Implementation Facilitation is an evidence-based strategy tailored to the specific needs of the clinic, designed to increase uptake of evidence based treatments for tobacco, alcohol and opioid use disorders. Will include provider education and academic detailing.~* External Facilitator: Outside content expert who assists site~* Local Champion: Site stakeholder who promotes change~* Provider Education and Academic Detailing: Provision of unbiased peer education~* Stakeholder Engagement: Aligning goals of implementation and those impacted~* Tailor Program to Site: Addressing site specific needs based on Aim 1~* Performance Monitoring and Feedback: Assess implementation of screening and treatment efforts and inform site of results~* Formative Evaluation: Quant. and qual. determination of impact~* Establish a Learning Collaborative: Shared learning opportunities tailored to stakeholders~* Program Marketing: Increase attention to availability of on-site addiction treatment services
Study NCT00872729 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cystagon®
Description: Reference Product: Cystagon® (Cysteamine Bitartrate) Capsules, 150 mg/50 mg.~Duration of Treatment and Dose: Reference Period up to four doses Q6H.
Study NCT00872729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RP103
Description: Test Product: RP103 (Cysteamine Bitartrate) Delayed-release Capsules, 75 mg.~Duration of treatment and Dose: Single dose of Test Product at dose equivalent to Reference Product.
Study NCT03427463 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: receiving 0.1 mg IT morphine
Description: Patients will receive the standard of care dose 0.1 mg of intrathecal morphine
Study NCT03427463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recieving 0.05 mg IT morphine
Description: Patients will receive 0.05 mg of intrathecal morphine
Study NCT03296618 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NSI-566
Description: Dosing will consist of a one-time stereotactic, intracranial injection of a hNSC line, NSI-566, ranging from 1.2×107 cells to 8×107 cells, as tolerated.
Study NCT04537949 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT162b3
Description: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (Prime/Boost (P/B) regimen).
Study NCT04049565 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Procalcitonin biomarker and CRP biomarker
Description: collecting blood samples to measure serum CRP and Procalcitonin
Study NCT04056728 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Eupenta Inj.
Description: fully liquid pentavalent vaccine, Adsorbed Diphtheria-Tetanus-whole-cell Pertussis-Hepatitis B (rDNA \[recombinant-deoxyribonucleic acid\])-Haemophilus influenzae type b conjugate vaccine single dose 0.5 mL/vial The vaccine is given at 6, 10 and 14 weeks of age in infants.
Study NCT01253382 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ecallantide
Description: 10 - 30mg subcutaneous injection.
Study NCT00368368 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GK Activator (2)
Description: 100mg po
Study NCT01408498 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone
Description: Topical administration of testosterone gel. Participants receive a one-time, single dose of 10 g of 1% testosterone gel.
Study NCT01253382 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: ecallantide
Description: 10 - 30mg subcutaneous injection.
Study NCT03876353 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Floss
Description: All participants will have half of their mouth flossed. Each participant will act as their own control.
Study NCT03828994 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tech-PN
Description: * text messaging(daily medication reminders and tri-weekly messages following the 14-day treatment period)~* enhanced community health nurse visits on day 3-5, 14 and 30~* field based treatment visits~* clinical assistance with notification, testing and treatment
Study NCT02281084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Azacitidine
Description: Oral azacitidine (AZA) 100 mg, 150 mg, or 200 mg tablets twice daily (BID) on days 1 to 21 of each 28-day treatment cycle. Participants continued to receive their assigned study treatment unless disease progression, unacceptable toxicity, lost to follow-up or withdrawal by participant occurred.
Study NCT02281084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab 1500 mg by IV infusion on Day 1 of each 28 day treatment cycle.
Study NCT02186067 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Referral System
Description: Primary Level:~Refer patients to secondary care centre if Patients has complicated hypertension (Patients with target organ damage, CVD, CKD or more the 3 drugs)~Secondary Level:~Community health center at Aga Khan University will serve as the secondary care center.~Family physician will manage patients with CVD, CKD or more than 3 drugs.~Tertiary care:~Cardiologist at the Aga Khan University will manage secondary, resistant and difficult to treat hypertension.~Behavioral: Other Interventions CME session by Cardiologist/Consultant Family Physician : At start , and at two months Community screening by Family physicians at the primary care center (open house) once in three months Patient group education session. Once in three months
Study NCT03192020 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous needle fasciotomy (PNF)
Description: The division of the cord can be made under local anesthesia in the clinic and takes only a few minutes to perform. It can be performed whenever the cord is palpable. There are only puncture wounds left, and hence, the patient can start normal use of the hand the day after the procedure. If patient seeks for a treatment and the recurrence of the disease can not be treated by the PNF or patient is not willing to new PNF patient will be treated with LF.
Study NCT03192020 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Collagenase Clostridium Histolyticum (CCH) 2.9 MG/ML [Xiaflex]
Description: CCH chemically dissolves type I collagen of which the cord is composed of. It is injected inside the cord at least three different places in the outpatient clinic and the cord can be ruptured by gently force after one to three days. If patient seeks for a treatment and the recurrence of the disease can not be treated by the CCH or patient is not willing to new CCH patient will be treated with LF.
Study NCT03192020 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Limited fasciectomy (LF)
Description: LF is performed in general or regional anesthesia in operating room. Constricting cords will be excised under direct vision. LF has been the dominant technique of surgical treatment. If patient seeks for a treatment the recurrence of the disease will be treated with LF as long as needed.
Study NCT03192020 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Limited fasciectomy (LF)
Description: LF is performed in general or regional anesthesia in operating room. Constricting cords will be excised under direct vision. LF has been the dominant technique of surgical treatment. If patient seeks for a treatment the recurrence of the disease will be treated with LF as long as needed.
Study NCT03382600 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg Q3W on Day 1 by IV infusion
Study NCT03382600 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 130 mg/m\^2 Q3W on Day 1 by IV infusion
Study NCT03382600 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TS-1
Description: 40 to 60 mg orally according to Body Surface Area (BSA) BID Q3W on Days 1-14
Study NCT03158584 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intrathecal Morphine
Description: Intrathecal administration of Morphine in children undergoing major abdominal surgeries
Study NCT01217749 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PCI-32765
Description: 420 mg PO daily
Study NCT01217749 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ofatumumab
Description: per package insert as an IV infusion
Study NCT04439578 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR6390 tablet single oral dose of SHR6390 or co-administered with rifampicin
Description: 600 mg rifampicin was administered in the morning.
Study NCT03988595 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Treatment
Description: Exercise sessions will consist of individualized, walking delivered following a non-linear (i.e.,exercise intensity is continually altered and progressed in conjunction with appropriate rest/recovery sessions across the entire intervention period) dosing schedule up to 7 individual treatment sessions/wk for 6 months. Remote supervised exercise sessions will be implemented and monitored using TeleEx. General physical activity as well as exercise performed outside of the structured treatment sessions will be evaluated via continuous monitoring using MSK approved telemedicine / wireless technology.
Study NCT04442646 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: multidisciplinary lessons
Description: the multidisciplinary lessons will be conducted by study staff, formed by pneumologist, nurse, biologist and respiratory therapist once a week within 1 month after randomization. Study staff will deal with the following topics: asthma physiopathology, recognition of asthma symptoms and exacerbation, educational interventions on therapy and device, nutritional counselling if necessary. Patients will receive a paper diary for symptoms and an expiratory pick flow meter (PFM) to be done twice a day
Study NCT04529772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acalabrutinib
Description: Investigational Product
Study NCT04529772 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo comparator
Study NCT04529772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Investigational Product
Study NCT04529772 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisone
Description: Investigational Product
Study NCT04529772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Investigational Product
Study NCT04529772 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rituximab
Description: Investigational Product
Study NCT04529772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Investigational Product
Study NCT04529772 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cyclophosphamide
Description: Investigational Product
Study NCT04529772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Investigational Product
Study NCT04529772 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vincristine
Description: Investigational Product
Study NCT04529772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Investigational Product
Study NCT04529772 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Doxorubicin
Description: Investigational Product
Study NCT04825314 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Urethral catheter
Description: All Patients will have urethral catheterization with either Noble Metal Alloy coated catheter or Silicon Foley catheter.
Study NCT01083719 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: FDG-PET
Description: Fluoro-deoxy gluocose-Positron emission tomography for delineating volumes in Glioblastoma
Study NCT00477594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mipomersen sodium
Description: 200 mg/ml, in 1 ml solution for subcutaneous injection.
Study NCT00418561 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rhASA - Dose Level 1
Description: Intravenous infusion 25 U/kg as a single dose - hereafter 50 U/kg every other week for 26 weeks
Study NCT00418561 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rhASA - Dose Level 2
Description: Intravenous infusion 100 U/kg every other week for 26 weeks
Study NCT00418561 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rhASA - Dose Level 3
Description: Intravenous infusion 200 U/kg every other week for 26 weeks
Study NCT03083574 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Photopheresis Theraflex ECP™
Description: The Macopharma (Theraflex ECP™) approach is based on a multistep procedure involving (1) standard mononuclear cell apheresis, (2) injection of the 8-Mop in the apheresis bag, (3) UVA exposure of the bag in the Macogenic illumination device, and (4) reinfusion of the cells into the patients.
Study NCT03081481 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRX302
Description: Single prostate cancer lesion injected with PRX302
Study NCT03919435 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trimethoprim Sulfamethoxazole
Description: Dosage: 160mg-800mg Frequency: 2 times a day Dosage Form: Pill (oral) Duration: 4 weeks
Study NCT05620511 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness based stress reduction
Description: Mindfulness based stress reduction v.s.Relaxation
Study NCT05620511 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Mindfulness based stress reduction
Description: Mindfulness based stress reduction v.s.Relaxation
Study NCT02566122 — intervention group
Intervention type: OTHER
Intervention: measurements
Study NCT00840866 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cefprozil
Description: 500 mg Tablet
Study NCT00840866 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefzil®
Description: 500 mg Tablet
Study NCT01501955 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Metaphyseal Hip Prosthesis
Description: Metaphyseal Hip Prosthesis (MHP) hip replacement
Study NCT01501955 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Stanmore
Description: Stanmore hip prosthesis
Study NCT00781339 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sodium 2-(dichloroamino)-2-methylpropane-1-sulfonate monohydrate
Description: 0.1% NVC-422 in saline, up to 100 mL, Study Part 1 - once on Day 1 held in the bladder for 1 hour; Study Part 2 (Part 2a - 0.1% NVC-422, Part 2b - 0.2% NVC-422), once daily for 7 days, held in the bladder for 1 hour
Study NCT01010503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tocilizumab [RoActemra/Actemra]
Description: tocilizumab 8 mg/kg intravenous infusion once in 4 weeks